Predictive Modeling: A New Paradigm for Managing Endometrial Cancer

Annals of Surgical Oncology

Volumn 23, Issue 3, 2016, Pages 975-988

  Bendifallah, Sofiane ^a,b   Daraï, Emile ^a,c   Ballester, Marcos ^a,c  

^a HÔPITAL TENON   (France)

^b INSERM   (France)

^c CENTRE DE RECHERCHE SAINT ANTOINE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL CLASSIFICATION; CLINICAL DECISION MAKING; ENDOMETRIUM CANCER; FEMALE; HUMAN; LYMPH NODE METASTASIS; PREDICTION; REVIEW; DECISION MAKING; DISEASE COURSE; DISEASE MANAGEMENT; ENDOMETRIAL NEOPLASMS; NOMOGRAM; RISK ASSESSMENT; STATISTICAL MODEL;

DECISION MAKING; DISEASE MANAGEMENT; DISEASE PROGRESSION; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; MODELS, STATISTICAL; NOMOGRAMS; RISK ASSESSMENT;

EID: 84957841815     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-015-4924-2     Document Type: Review

References (68)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65:5–29.
2. Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet. 2009;105;103–4.
3. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63: 11–30.
4. Creasman WT, Odicino F, Maisonneuve P, et al. Carcinoma of the corpus uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet. 2006;95 Suppl 1:S105–43.
5. Kinkel K, Forstner R, Danza FM, et al. Staging of endometrial cancer with MRI: guidelines of the European Society of Urogenital Imaging. Eur Radiol. 2009;19:1565–74.
6. Haldorsen IS, Salvesen HB. Staging of endometrial carcinomas with MRI using traditional and novel MRI techniques. Clin Radiol. 2012;67:2–12.
7. Ballester M, Dubernard G, Lécuru F, et al. Detection rate and diagnostic accuracy of sentinel-node biopsy in early stage endometrial cancer: a prospective multicentre study (SENTI-ENDO). Lancet Oncol. 2011;12:469–76.
8. Salvesen HB, Haldorsen IS, Trovik J. Markers for individualised therapy in endometrial carcinoma. Lancet Oncol. 2012;13:e353–61.
9. Morneau M, Foster W, Lalancette M, et al. Adjuvant treatment for endometrial cancer: literature review and recommendations by the Comité de l’évolution des pratiques en oncologie (CEPO). Gynecol Oncol. 2013;131:231–40.
10. Colombo N, Preti E, Landoni F, et al. Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24 Suppl 6:vi33–38.
11. Koh W-J, Greer BE, Abu-Rustum NR, et al. Uterine neoplasms, version 1. 2014. J Natl Compr Cancer Netw. 2014;12:248–80.
12. Querleu D, Planchamp F, Narducci F, et al. Clinical practice guidelines for the management of patients with endometrial cancer in France: recommendations of the Institut National du Cancer and the Société Française d’Oncologie Gynécologique. Int J Gynecol Cancer. 2011;21:945–50.
13. Hogarth RM, Karelaia N. Heuristic and linear models of judgment: matching rules and environments. Psychol Rev. 2007;114:733–58.
14. Vlaev I, Chater N. Game relativity: how context influences strategic decision making. J Exp Psychol Learn Mem Cogn. 2006;32:131–49.
15. Kattan MW, Scardino PT. Prediction of progression: nomograms of clinical utility. Clin Prostate Cancer 2002;1:90–6.
16. Dedes KJ, Wetterskog D, Ashworth A, Kaye SB, Reis-Filho JS. Emerging therapeutic targets in endometrial cancer. Nat Rev Clin Oncol. 2011;8:261–71.
17. Weigelt B, Banerjee S. Molecular targets and targeted therapeutics in endometrial cancer. Curr Opin Oncol. 2012;24:554–63.
18. Tian Q, Price ND, Hood L. Systems cancer medicine: towards realization of predictive, preventive, personalized and participatory (P4) medicine. J Intern Med. 2012;271:111–21.
19. Eastham JA, Kattan MW, Scardino PT. Nomograms as predictive models. Semin Urol Oncol. 2002;20:108–15.
20. Abu-Rustum NR, Zhou Q, Gomez JD, et al. A nomogram for predicting overall survival of women with endometrial cancer following primary therapy: toward improving individualized cancer care. Gynecol Oncol. 2010;116:399–403.
21. AlHilli MM, Podratz KC, Dowdy SC, et al. Risk-scoring system for the individualized prediction of lymphatic dissemination in patients with endometrioid endometrial cancer. Gynecol Oncol. 2013;131:103–08.
22. AlHilli MM, Podratz KC, Dowdy SC, et al. Preoperative biopsy and intraoperative tumor diameter predict lymph node dissemination in endometrial cancer. Gynecol Oncol. 2013;128:294–9.
23. Bendifallah S, Genin AS, Naoura I, et al. A nomogram for predicting lymph node metastasis of presumed stage I and II endometrial cancer. Am J Obstet Gynecol. 2012;207:197.e1–8.
24. Kamura T, Yahata H, Shigematsu T, et al. Predicting pelvic lymph node metastasis in endometrial carcinoma. Gynecol Oncol. 1999;72:387–91.
25. Lee J-Y, Jung DC, Park SH, et al. Preoperative prediction model of lymph node metastasis in endometrial cancer. Int J Gynecol Cancer. 2010;20:1350–55.
26. Todo Y, Okamoto K, Hayashi M, et al. A validation study of a scoring system to estimate the risk of lymph node metastasis for patients with endometrial cancer for tailoring the indication of lymphadenectomy. Gynecol Oncol. 2007;104:623–28.
27. Bendifallah S, Canlorbe G, Huguet F, et al. A risk scoring system to determine recurrence in early-stage type 1 endometrial cancer: a French Multicentre Study. Ann Surg Oncol. 2014; doi: 10.1245/s10434-014-3864-6
28. Bendifallah S, Canlorbe G, Arsène E, et al. French multicenter study evaluating the risk of lymph node metastases in early-stage endometrial cancer: contribution of a risk scoring system. Ann Surg Oncol. 2015; doi: 10.1245/s10434-014-4311-4
29. Kondalsamy-Chennakesavan S, Yu C, Kattan MW, et al. Nomograms to predict isolated loco-regional or distant recurrence among women with uterine cancer. Gynecol Oncol. 2012;125:520–25.
30. Kattan MW. Nomograms are superior to staging and risk grouping systems for identifying high-risk patients: preoperative application in prostate cancer. Curr Opin Urol. 2003;13:111–16.
31. Barlin JN, Soslow RA, Lutz M, et al. Redefining stage I endometrial cancer: incorporating histology, a binary grading system, myometrial invasion, and lymph node assessment. Int J Gynecol Cancer. 2013;23:1620–28.
32. Murali R, Soslow RA, Weigelt B. Classification of endometrial carcinoma: more than two types. Lancet Oncol. 2014;15:e268–278.
33. Creutzberg CL, van Putten WL, Koper PC, et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet 2000;355:1404–11.
34. Keys HM, Roberts JA, Brunetto VL, et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2004;92:744–51.
35. Todo Y, Kato H, Kaneuchi M, et al. Survival effect of para-aortic lymphadenectomy in endometrial cancer (SEPAL study): a retrospective cohort analysis. Lancet. 2010;375:1165–72.
36. Bendifallah S, Canlorbe G, Raimond E, et al. A clue towards improving the European Society of Medical Oncology risk group classification in apparent early stage endometrial cancer? Impact of lymphovascular space invasion. Br J Cancer. 2014; doi: 10.1038/bjc.2014.237
37. Bendifallah S, Canlorbe G, Collinet P, et al. Just how accurate are the major risk stratification systems for early-stage endometrial cancer? Br. J. Cancer (2015). doi:10.1038/bjc.2015.35
38. Silverman MB, Roche PC, Kho RM, et al. Molecular and cytokinetic pretreatment risk assessment in endometrial carcinoma. Gynecol Oncol. 2000;77:1–7.
39. Cancer Genome Atlas Research Network, Kandoth C, Schultz N, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497:67–73.
40. Iasonos A, Schrag D, Raj GV, Panageas KS. How to build and interpret a nomogram for cancer prognosis. J Clin Oncol. 2008;26:1364–70.
41. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15:361–87.
42. Abbott RD. Logistic regression in survival analysis. Am J Epidemiol. 1985;121:465–71.
43. Hosmer DW, Hjort NL. Goodness-of-fit processes for logistic regression: simulation results. Stat Med. 2002;21:2723–38.
44. Steyerberg EW, Eijkemans MJ, Van Houwelingen JC, Lee KL, Habbema JD. Prognostic models based on literature and individual patient data in logistic regression analysis. Stat Med. 2000;19:141–60.
45. American College of Obstetricians and Gynecologists. ACOG practice bulletin, clinical management guidelines for obstetrician-gynecologists, number 65, August 2005: management of endometrial cancer. Obstet Gynecol. 2005;106:413–25.
46. Ko EM, Funk MJ, Clark LH, Brewster WR. Did GOG99 and PORTEC1 change clinical practice in the United States? Gynecol Oncol. 2013;129:12–17.
47. ASTEC study group. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet. 2009;373:125–36.
48. Nout RA, Smit VT, Putter H, et al. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. Lancet. 2010;375:816–23.
49. Benedetti Panici P, Basile S, Maneschi F, et al. Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst. 2008;100:1707–16.
50. Nugent EK, Bishop EA, Mathews CA, et al. Do uterine risk factors or lymph node metastasis more significantly affect recurrence in patients with endometrioid adenocarcinoma? Gynecol Oncol. 2012;125:94–98.
51. Creasman WT, Morrow CP, Bundy BN, et al. Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study. Cancer. 1987;60:2035–41.
52. Podratz KC, Mariani A, Webb MJ. Staging and therapeutic value of lymphadenectomy in endometrial cancer. Gynecol Oncol. 1998;70:163–64.
53. Mariani A, Webb MJ, Keeney GL, Lesnick TG, Podratz KC. Surgical stage I endometrial cancer: predictors of distant failure and death. Gynecol Oncol. 2002;87:274–80.
54. Lurain JR, Rice BL, Rademaker AW, et al. Prognostic factors associated with recurrence in clinical stage I adenocarcinoma of the endometrium. Obstet Gynecol. 1991;78:63–69.
55. Kim HS, Suh DH, Kim MK, et al. Systematic lymphadenectomy for survival in patients with endometrial cancer: a meta-analysis. Jpn J Clin Oncol. 2012;42:405–12.
56. Luomaranta, A., Leminen, A. & Loukovaara, M. Prediction of lymph node and distant metastasis in patients with endometrial carcinoma: a new model based on demographics, biochemical factors, and tumor histology. Gynecol Oncol. 2013;129:28–32.
57. Koskas M, Genin AS, Graesslin O, et al. Evaluation of a method of predicting lymph node metastasis in endometrial cancer based on five pre-operative characteristics. Eur J Obstet Gynecol Reprod Biol. 2014;172:115–19.
58. Bendifallah S, Canlorbe G, Raimond E, et al. An external validation study of nomograms designed to predict isolated loco-regional and distant endometrial cancer recurrences: how applicable are they? Br J Cancer. 2013; doi: 10.1038/bjc.2013.500
59. Kang S, Lee JM, Lee JK, et al. A Web-based nomogram predicting para-aortic nodal metastasis in incompletely staged patients with endometrial cancer: a Korean Multicenter Study. Int J Gynecol Cancer. 2014;24:513–19.
60. Brinton LA, Felix AS, McMeekin DS, et al. Etiologic heterogeneity in endometrial cancer: evidence from a Gynecologic Oncology Group trial. Gynecol Oncol. 2013;129:277–84.
61. Polterauer S, Zhou Q, Grimm C, et al. External validation of a nomogram predicting overall survival of patients diagnosed with endometrial cancer. Gynecol Oncol. 2012;125:526–30.
62. Koskas M, Bendifallah S, Luton D, Darai E, Rouzier R. Independent external validation of radiotherapy and its impact on the accuracy of a nomogram for predicting survival of women with endometrial cancer. Gynecol Oncol. 2011;123:214–20.
63. AlHilli MM, Mariani A, Bakkum-Gamez JN, et al. Risk-scoring models for individualized prediction of overall survival in low-grade and high-grade endometrial cancer. Gynecol Oncol. 2014;133:485–93.
64. Creutzberg CL, van Stiphout RG, Nout RA, et al. Nomograms for prediction of outcome with or without adjuvant radiation therapy for patients with endometrial cancer: a pooled analysis of PORTEC-1 and PORTEC-2 Trials. Int J Radiat Oncol Biol Phys. 2015;91:530–39.
65. Lakhman Y, Yakar D, Goldman DA, et al. Preoperative CT-based nomogram for predicting overall survival in women with non-endometrioid carcinomas of the uterine corpus. Abdom Imaging 2014; doi: 10.1007/s00261-014-0337-0
66. Bendifallah S, Canlorbe G, Raimond E, et al. External validation of nomograms designed to predict lymphatic dissemination in patients with early-stage endometrioid endometrial cancer: a multicenter study. Am J Obstet Gynecol. 2014; doi: 10.1016/j.ajog.2014.06.058
67. Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 1983;15:10–17.
68. Kattan MW. Nomograms. Introduction. Semin Urol Oncol. 2002;20:79–81.